From DCAT Value Chain Insights (VCI)
Biogen has appointed Alisha A. Alaimo as senior vice president of US therapeutic operations, where she will lead sales and marketing, market access, patient services, and commercial operations and strategy.
Alaimo will join Biogen from Novartis, where she was vice president and head of its cardiovascular business unit. At Biogen, she will work to drive the uptake of the company’s portfolio of multiple sclerosis therapies and increase access for Spinraza, a treatment for spinal muscular atrophy. Alaimo will also work to prepare the US market for potential approvals of new therapies from across the company’s late-stage neuroscience pipeline. She will report directly to Chief Executive Officer Michel Vounatsos.
Over a 17-year career at Novartis, Alaimo took on positions of increasing responsibility in the US, UK, and Switzerland. Prior to heading the cardiovascular unit, she oversaw the company’s neuroscience business unit.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription